Boston Scientific Corporation (NYSE:BSX) on Tuesday reported positive pivotal trial data for its investigational SEISMIQ 4CE Coronary Intravascular Lithotripsy catheter, with the device meeting both primary safety and effectiveness goals in patients with severely calcified coronary artery disease.
The study evaluated the use of the coronary intravascular lithotripsy (IVL) catheter in patients undergoing percutaneous coronary intervention procedures.
Something went wrong.
Trial Met Safety And Effectiveness Endpoints
The trial enrolled 420 patients with severe coronary artery disease.
